Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ecp Clear all
Recruiting Phase 2 Interventional

Photopheresis in Early-stage Mycosis Fungoides

NCT05680558
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 6, 2026, 2:32 PM EDT
Withdrawn Phase 2 Interventional

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
Biological
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 6, 2026, 2:32 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Best available Treatment (BAT)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

NCT00221026
View directory record Official record
Conditions
Crohn's Disease
Interventions
Methoxsalen +ECP, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Bethesda, Maryland • Chevy Chase, Maryland • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 6, 2026, 2:32 PM EDT
Recruiting Phase 2 Interventional

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

NCT04930653
View directory record Official record
Conditions
Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
Interventions
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

NCT04446182
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Itacitinib, Extracorporeal Photopheresis (ECP)
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional Results available

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

NCT01380535
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ECP Methoxsalen, Standard of Care
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 6, 2026, 2:32 PM EDT
Active, not recruiting Not applicable Interventional

Impella ECP Early Feasibility Study

NCT04477603
View directory record Official record
Conditions
High-risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Paramus, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Not applicable Interventional Results available

Wave Crossover ECP Study for Simplified Therapy

NCT06571370
View directory record Official record
Conditions
Chronic Stable Angina, Refractory Angina
Interventions
External Counterpulsation
Device
Lead sponsor
Pression
Industry
Eligibility
35 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Monroe, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Enrolling by invitation Not applicable Interventional

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

NCT05334784
View directory record Official record
Conditions
High-Risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of an Edible Colonoscopy Preparation

NCT03332485
View directory record Official record
Conditions
Colon Prep for Colonoscopy
Interventions
ECP Colon Prep Kit, MoviPrep®
Drug
Lead sponsor
Sebela Pharmaceuticals Development LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
8
States / cities
Anaheim, California • Indianapolis, Indiana • Bastrop, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 6, 2026, 2:32 PM EDT
Recruiting Not applicable Interventional

External Post-Operative Skull Prosthesis to Prevent Sunken Flap Syndrome in Craniectomy Patients

NCT06899711
View directory record Official record
Conditions
Craniectomy, Trephined Syndrome, Traumatic Brain Injury (TBI) Patients, Ischemic Stroke
Interventions
External Cranial Prosthesis
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Recruiting No phase listed Observational

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions
Not listed
Lead sponsor
Brian Keller
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability Study of an Edible Colon Preparation

NCT02402270
View directory record Official record
Conditions
Bowel Preparation
Interventions
NuLYTELY® (PEG 3350), ECP-019, MoviPrep® (PEG 3350)
Drug
Lead sponsor
ColonaryConcepts LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Not applicable Interventional Results available

ACCESS: AI for pediatriC diabetiC Eye examS Study

NCT05131451
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Point of Care Autonomous AI diabetic retinopathy exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 6, 2026, 2:32 PM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Phase 4 Interventional

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

NCT00221039
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
Methoxsalen+ECP
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 6, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional

Reduced Intensity Transplant Using Extracorporeal Photopheresis

NCT00179790
View directory record Official record
Conditions
Leukemia, Cancer
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 6, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 6, 2026, 2:32 PM EDT
Terminated No phase listed Observational

Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

NCT02151539
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
medical chart review, quality-of-life assessment
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 6, 2026, 2:32 PM EDT
Terminated Phase 1Phase 2 Interventional

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

NCT04676087
View directory record Official record
Conditions
Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
Interventions
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment
Procedure · Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 6, 2026, 2:32 PM EDT
Completed No phase listed Observational

Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis

NCT03851601
View directory record Official record
Conditions
GVHD
Interventions
blood samples
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 6, 2026, 2:32 PM EDT